Drugs / ABSK061
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07007546 | May → Jul 2025 | — | Abbisko Therapeutics Co, Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05244551 | Jun 2022 → Apr 2025 overdue | cancer | Abbisko Therapeutics Co, Ltd | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07297875 | Dec 2025 → Dec 2028 expected | achondroplasia | Abbisko Therapeutics Co, Ltd | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06632262 | Nov 2024 → Nov 2029 expected | gastroesophageal cancer, non-small cell lung carcinoma, urothelial carcinoma | Abbisko Therapeutics Co, Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABSK061 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06632262 ↗ |
| Action | Inhibit | “ABSK061 is a selective and potent pan FGFR 2/3 inhibitor” NCT06632262 ↗ |
| Route | Oral | “oral ABSK061” NCT05244551 ↗ |